NCT04455555View on ClinicalTrials.gov

Efficacy and Safety of Rotigotine in the Treatment of Patients With Early Stage of Primary Parkinson's Disease

PHASE3CompletedINTERVENTIONAL
Enrollment

294

Participants

Timeline

Start Date

August 1, 2018

Primary Completion Date

February 1, 2019

Study Completion Date

February 1, 2019

Conditions
Parkinson's Disease
Interventions
DRUG

LY03003( the name of rotigotine)

LY03003 (Continuous Dopamine Stimulation) sustained release microspheres / injection once a week 4 weeks followed by 24 weeks until 28 weeks.

OTHER

Placebo

Null sustained release microspheres placebo / injection once a week 4 weeks followed by 24 weeks until 28 weeks.

Trial Locations (1)

100191

Peking University Third Hospital, Beijing

All Listed Sponsors
lead

Peking University Third Hospital

OTHER

NCT04455555 - Efficacy and Safety of Rotigotine in the Treatment of Patients With Early Stage of Primary Parkinson's Disease | Biotech Hunter | Biotech Hunter